Jerome J. Chetritt

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Comparison of an AI-based prognostic assay with gene expression profiling in early-stage melanoma.

Comparison of an AI-based prognostic assay with gene expression profiling in early-stage melanoma.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 05, 2026

Deep learning-based prediction of homologous recombination deficiency from histopathological whole-slide images in ovarian cancer.

Deep learning-based prediction of homologous recombination deficiency from histopathological whole-slide images in ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: November 27, 2025

Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancer.

Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancer.

Journal: NPJ digital medicine

Published: August 19, 2025

Real-world analysis of HER2-ultralow in HR+/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomes.

Real-world analysis of HER2-ultralow in HR+/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomes.

Journal: Therapeutic advances in medical oncology

Published: May 02, 2025

Risk score stratification of cutaneous melanoma patients based on whole slide images analysis by deep learning.

Risk score stratification of cutaneous melanoma patients based on whole slide images analysis by deep learning.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 10, 2024

The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression.

The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: March 28, 2019

The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status.

The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status.

Journal: Oncoimmunology

Published: September 20, 2018

Clinical, histological, and molecular risk factors for cancer recurrence in patients with stage II colon cancer.

Clinical, histological, and molecular risk factors for cancer recurrence in patients with stage II colon cancer.

Journal: European journal of gastroenterology & hepatology

Published: September 09, 2016

uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management

uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management

Journal: Bulletin du cancer

Published: August 04, 2015

uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management

uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management

Journal: Annales de pathologie

Published: April 23, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026